De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC

By News Health
12 hours Ago

(MedPage Today) — Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week non-anthracycline regimen in…

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/114604

Author :

Publish date : 2025-03-11 20:39:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Investigational Alopecia Areata Drug Shows Sustained Effect

Phone-Based Walking Support Program Enhances Arthritis Care

Lithium in Drinking Water Linked to Reduced Cancer Risk

Doctors try to stop under-eights drinking slushies

NHS to offer take-at-home tablet

Four Charged in Death of Young Boy 'Incinerated' in Hyperbaric Chamber Explosion